It is understood that Epistine Hydrochloride Eye Drops are mainly used to treat allergic conjunctivitis. Allergic conjunctivitis is a type of disease caused by hypersensitivity reactions of the conjunctiva to allergen stimuli, including non proliferative allergic conjunctivitis (seasonal allergic conjunctivitis and perennial allergic conjunctivitis) and proliferative allergic conjunctivitis (spring keratoconjunctivitis, papillary conjunctivitis, and atopic keratoconjunctivitis).

 

 

 

In China, seasonal allergic conjunctivitis and perennial allergic conjunctivitis account for 74% of all allergic conjunctivitis patients. Currently, it is the peak period for seasonal allergic conjunctivitis, characterized by a series of symptoms such as itching, increased filamentous discharge, and redness of the eyes.

 

 

 

The Epistine Hydrochloride Eye Drops approved by Runer Ophthalmology this time belong to histamine H1 receptor antagonists and mast cell stabilizers, which can effectively block the release of allergic mediators such as histamine, leukotriene C4, platelet activating factor (PAF), and serotonin, relieve symptoms such as eye itching and redness. After medication, the drug concentration is almost undetectable in the blood, and high concentrations are mainly concentrated in eye tissues such as eyelids, iris, conjunctiva, and cornea, which can ensure effective local action.

 

 

 

Data statistics show that the domestic market for the treatment of allergic conjunctivitis has a scale of nearly 1 billion yuan. With the launch of the first imitation product of Runer Ophthalmology, it is expected that there will be new changes in the competitive landscape of the market. It is worth noting that in addition to Runer Ophthalmology, several domestic pharmaceutical companies have also established their presence in this field. Among them, similar products from Zhaoke Ophthalmology are already under approval, while related products from Hangzhou Baishan Technology and Tiansheng Pharmaceutical are also in the clinical trial stage.

 

 

 

Runer Ophthalmology is a technology innovation enterprise that integrates innovative drug research and development, production, and sales, with a strategic direction of global first drug research and development and global market. It has an independently developed global first drug design platform and innovative drug formulation technology platform, committed to researching and producing ophthalmic full course innovative drugs with global independent intellectual property rights, safety, effectiveness, and affordability for patients.

 

 

 

At present, the company has a presence in the field of ophthalmic diseases such as cataracts, glaucoma, ophthalmic immune system, and ophthalmic infections. In addition to Epistine Hydrochloride Eye Drops, Runer Ophthalmology has multiple new drugs that are already in clinical and even on the market stage.

 

 

 

As of 2024, its sodium bromide eye drops have been approved for sale. Brompheniramate sodium eye drops is the first drug approval obtained by Runer Ophthalmology since its establishment, suitable for symptomatic treatment of inflammatory diseases in the external and anterior eye areas, such as blepharitis, conjunctivitis, postoperative inflammation, etc.

 

 

 

In addition, there is a product under development called GOCS-H101 (the world's first), which is the first eye drop drug with reversible abnormal aggregation of lens proteins. It can significantly reverse cataracts and achieve a breakthrough in cataract drug treatment.